In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ESC Guidelines on ST-segment elevation myocardial infarction published today

Barcelona, Spain – 26 Aug 2017: European Society of Cardiology (ESC) Guidelines on the management of acute myocardial infarction in patients with ST-segment elevation are published online today in European Heart Journal, (1) and on the ESC website. (2)

The document provides recommendations on topics not covered by the 2012 Guidelines and changes some previous recommendations following new evidence.

For the first time there is a clear definition of when to start the clock for the 90 minute target to treat patients with percutaneous coronary intervention (PCI). The clock should start at the time of ST-segment elevation myocardial infarction (STEMI) diagnosis by electrocardiogram (ECG).

“Until now there was confusion over whether the clock starts when the patient has the first symptoms, when he or she calls the emergency services, when the ambulance arrives on the scene, or when the patient arrives at the hospital,” said Task Force Chairperson Prof Stefan James (Sweden). “We don’t know if the patient is suffering from STEMI until the ECG so this is a sensible starting point and the vessel should be opened within 90 minutes from then.”

The vague term door-to-balloon has been removed from the guidelines and first medical contact (FMC) is defined as the time point when the patient is initially assessed by a physician, paramedic or nurse who obtains and interprets the ECG. “Door-to-balloon is no longer a useful term,” said Task Force Chairperson Dr Borja Ibanez (Spain). “Treatment used to be initiated in the hospital but now it can start in the ambulance so the ‘door’ varies according to the situation.”

In cases where fibrinolysis is the reperfusion strategy, the maximum time delay from the diagnosis of STEMI to treatment has been shortened from 30 minutes in 2012 to 10 minutes in 2017.

Complete revascularization was not recommended in the 2012 document which said that only infarct-related arteries should be treated. Today’s guidelines state that complete revascularization should be considered, with non-infarct-related arteries treated during the index procedure or another time point before discharge from hospital.

Thrombus aspiration is no longer recommended, based on two large trials in more than 15 000 patients. Also not recommended is deferred stenting, which involved opening the artery and waiting 48 hours to implant a stent. Regarding PCI, the use of drug eluting stents instead of bare metal stents has gained a stronger recommendation as has the use of radial, instead of femoral, arterial access.

When it comes to medications, the authors state that dual antiplatelet therapy extension beyond 12 months in selected patients may be considered. Bivalirudin has been downgraded from class I to IIa, and enoxaparin upgraded from class IIb to IIa. Cangrelor, which was not mentioned in the 2012 document, has been recommended as an option in certain patients. Also new is a recommendation for additional lipid lowering therapy in patients with high cholesterol despite taking the maximum dose of statins.

The cut off for administering oxygen therapy has been lowered from less than 95% to less than 90% arterial oxygen saturation. Left and right bundle branch block are now considered equal for recommending urgent angiography when patients have ischaemic symptoms.

A chapter has been added on myocardial infarction with non-obstructive coronary arteries (MINOCA), which comprises up to 14% of STEMI patients and demands additional diagnostic tests and tailored therapy which may differ from typical STEMI.

Prof James said: “The guidelines contain a whole set of new didactic figures and straightforward recommendations to help clinicians diagnosis and treat STEMI patients within a tight schedule.”

Dr Ibanez said: “We collaborated with other ESC Guideline Task Forces producing documents for this year and next, especially on dual antiplatelet therapy and the universal definition of myocardial infarction, to ensure consistency.”

ENDS

Notes to editor

Sources of funding: None.

Disclosures: The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website www.escardio.org/guidelines

References:
(1) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2017. doi 10.1093/eurheartj/ehx393
(2) ESC Guidelines on the ESC website

Guidelines at ESC Congress:
The AMI-STEMI Guidelines will be featured in:
• ESC Guidelines 2017 – Overview on 27 August at 08:30
• ESC Guidelines 2017 – AMI-STEMI on 27 August at 14:00
• Meet the Guidelines Task Force – AMI-STEMI on 28 August at 15:40
• Congress Condensed – ESC Clinical Practice Guidelines 2017 on 30 August at 09:00

Associated Derivative Products can be found via the ESC website at:
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-derivative-products
Download the free ESC Pocket Guidelines App for all mobile devices: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-derivative-products/ESC-Mobile-Pocket-Guidelines


ESC Press Office

For more information, please contact the ESC Press Office: press@escardio.org.
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856
The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  


About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org.